Tools, data and AI companies at BIO‑Europe 2026
Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website
30 tools, data and AI companies are at BIO-Europe 2026 — 14 presentations on the program. Most represented: Sartorius (2 on the program), Evaluate (1 on the program), Deep Intelligent Pharma (1 on the program). 5 of them have their own page in this guide. As of Sep 29, 2026.
Track
Top represented
Showing 1–23 of 30 organizations
| Organization | BIO-Europe 2026 Attendance |
|---|---|
Sartorius Göttingen, Germany | |
Supplies bioprocess equipment, consumables and laboratory instruments for biopharmaceutical development and manufacturing. | Panel Mon Nov 9 14:00–14:45 Community Conversations – Session 1 Attendees join small-group lunch tables on a topic of their choice, from regulatory strategy and global launches to hiring talent and managing partnerships. Business of BiotechRegulatory Strategy Panel Mon Nov 9 15:00–15:45 Community Conversations – Session 2 A second round of the same small-group lunch tables, letting attendees switch to another topic such as regulatory strategy, launches or partnerships. Business of BiotechRegulatory Strategy |
Evaluate London, United Kingdom | ◆Platinum Sponsor |
Provides pharmaceutical market intelligence, including sales forecasts, pipeline and deal data. | Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Why AI that forms hypotheses and guides experiments could mean more drug candidates, not fewer scientists, and how to pick which to pursue. Ecosystem InnovationBusiness of Biotech Keynote Mon Nov 9 12:00–12:45 Building a competitive and impactful European biotech community: Perspectives from the European Life Sciences Coalition and CEOs How Europe can keep biotech talent, money and companies at home by drawing in big investors, speeding regulation and building stronger stock markets. Ecosystem InnovationBusiness of Biotech |
◆Platinum Sponsor | |
AI company offering AI-powered clinical development services and software, from protocol design and data management to regulatory documents. | Talk Mon Nov 9 09:00–10:00 Doctor-to-Doctor: A PI-Led Pathway into Japan Using AI, DCT, and Registration-Directed Investigator-Initiated Trials to Reach Japanese Patients Faster How trials led by the right Japanese doctor, rather than a contract research company, can take a drug toward approval in Japan. Clinical StrategyRegulatory Strategy |
AlphaSense New York, New York | |
Market intelligence platform using AI search across company filings, broker research, expert call transcripts and news. | Panel Mon Nov 9 13:00–13:45 The therapeutic landscape backed by analyst insights Which disease areas analysts rate most promising for new drugs and investment, and how new science and rule changes are reshaping them. |
Information and analytics company providing life sciences and healthcare data, market research and intellectual property services. | Panel Tue Nov 10 14:30–14:55 The Next Generation of European Entrepreneurs: From Scientific Innovation to Life Sciences Impact What makes a successful life sciences founder, and how founders in Europe can turn discoveries into biotech companies that compete worldwide. |
Dassault Systèmes Vélizy-Villacoublay, France | |
French software company whose life sciences portfolio includes BIOVIA scientific software and Medidata clinical trial software. | Panel Tue Nov 10 11:15–12:15 Women’s Health: Healthcare’s Largest Underserved Market and Biggest Growth Opportunity Why women's health is a large, neglected market, and how much value is lost when medicine is designed around the wrong default patient. Therapeutic InsightsBusiness of Biotech |
Clinical trial platform helping patients find trials and giving sponsors trial-planning intelligence through its TrialHub platform. | Panel Tue Nov 10 15:00–15:25 Expanding Global Clinical Trials: Opportunities and Challenges in Emerging Markets How to expand clinical trials into emerging markets and underserved groups, from picking contract research companies and sites to building local partnerships. |
Form Bio Dallas, TX | |
Software and AI platform for designing and manufacturing cell and gene therapies. | Panel Mon Nov 9 16:00–16:45 Cell and Gene Therapy: What Should You Know? Where cell and gene therapies stand today, what recent clinical and sales data show, and how funding and partnerships are changing. |
GenAIz Montreal, Canada | |
AI software company helping pharmaceutical and life sciences organizations connect and analyze their data. | Panel Mon Nov 9 14:00–14:25 Get in the Mix with Canada’s Picks: Innovation in Life Sciences Selected Canadian companies present their health technologies, alongside an overview of Canada's life sciences sector and its partnership opportunities. |
Ingenix Warsaw, Poland | |
AI company whose Biological Reasoning Engine supports translational and clinical R&D decisions for pharma and biotech partners. | Panel Mon Nov 9 17:00–17:45 AI in the Lab: Why Greater Efficiency Could Mean More Drugs, Not Fewer Scientists Why AI that forms hypotheses and guides experiments could mean more drug candidates, not fewer scientists, and how to pick which to pursue. Ecosystem InnovationBusiness of Biotech |
Luna Therapeutics Cambridge, United Kingdom | |
Makes CytoStrat customizable microcarriers, clinical-grade biomaterials for bioprocessing and cell therapy. | Talk Mon Nov 9 15:00–16:15 Merck's EMEA Advance Biotech Grant Program Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market. |
Pharmaceutical data and intelligence group whose businesses include Citeline, Evaluate and MMIT. | Panel Mon Nov 9 11:00–11:45 Unlocking Pharma’s Productivity Potential Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive. Business of Biotech |
A-Alpha Bio Seattle, WA | |
Measures protein–protein interactions at large scale and uses the data with machine learning to help engineer protein medicines. | |
Offers an AI platform that analyses omics data for researchers without any coding. | |
AinB Gwacheon, South Korea | |
Korean company using AI to design and optimise antibodies and to improve how antibodies are produced. | |
Uses machine learning to engineer proteins, raising production yield and quality for research tools and therapeutics. | |
Builds AI tools for drug manufacturing and quality control, including a virtual cell model for biomanufacturing. | |
Concr Cambridge, United Kingdom | |
Software company modelling biological risk in cancer drug development. | |
AI drug discovery company offering first-in-class discovery, allosteric and dual-target drug design, and its BioTrajectory AI platform. | |
Produces glycan building blocks at lower cost for specialty carbohydrates and therapeutic proteins. | |
Builds cell-based digital twins of long-term disease to predict drug safety in days without animal testing. | |
Kantify Brussels, Belgium | |
AI small-molecule discovery engine for targets with no known binders, used with partners to find new chemistry. | |
Builds oversight and decision software for clinical AI, adaptive trials and other high-stakes healthcare settings. |
Instantly find 20 buyers from tools, data and AI companies
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse BIO-Europe 2026 by
Organization type
Track
Everyone
Not affiliated with or endorsed by EBD Group, Informa Connect or BIO-Europe. Submit a correction